IQnovate to move to ASX
02 April, 2012 by Dylan Bushell-EmblingContract medical company IQnovate (NSX:IQN) will delist from the NSX and move its public share listing to the ASX.
Merged drug developer nears ASX listing
02 April, 2012 by Dylan Bushell-EmblingBioxyne (ASX:BSN), created from the merger of Hunter Immunology and Probiomics (ASX:PCC), is scheduled to list on the ASX in April.
Pharmaxis signs EU distribution deal for Bronchitol
30 March, 2012 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has signed a three-year deal with Aravo Healthcare covering distribution of its cystic fibrosis treatment across Europe.
Agenix on track for hepatitis B drug trial
30 March, 2012 by Dylan Bushell-EmblingMelbourne's Agenix (ASX:AGX) expects to be on time with an application to conduct a phase I trial of a prospective hepatitis B treatment in China.
Synchrotron funding to support ongoing research
29 March, 2012 by AusBiotechThe Australian Synchrotron has yesterday secured a $100 million, allowing the Melbourne-based facility to continue research, after the Federal and state governments pledged contributions.
Biota antiviral batters the common cold
29 March, 2012 by Dylan Bushell-EmblingBiota Holdings (ASX:BTA) has revealed the results of a successful phase IIb trial of its common cold treatment candidate, vapendavir.
Alchemia finalising oncology spin-off
29 March, 2012 by Dylan Bushell-EmblingBrisbane-based Alchemia (ASX:ACL) is in the last stages of planning for the proposed spin-off and IPO of its oncology unit.
Free listing on Australian biotech and medtech directories
27 March, 2012 by AusBiotechAusBiotech invites Australian companies to list their biotechnology and medical technology companies free on two national directories.
Bioniche licenses animal health products
26 March, 2012 by Dylan Bushell-EmblingCanada-based Bioniche (ASX:BNC) has scored an exclusive distribution deal covering four products for its animal health-focused Australian subsidiary.
Bionomics gets approval for ovarian cancer trial
26 March, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) has been cleared by the Food and Drug Administration to commence a phase I/II clinical trial of BNC105 as a treatment for ovarian cancer.
Avexa closer to EMA approval for ATC
23 March, 2012 by Dylan Bushell-EmblingAvexa Limited (ASX:AVX) and the EMA have agreed on the path forward to gaining European approval for drug-resistant HIV treatment ATC.
Starpharma kicks off phase III VivaGel trials
22 March, 2012 by Dylan Bushell-EmblingMelbourne's Starpharma Holdings (ASX:SPL) has commenced two phase III trials of VivaGel as a BV treatment, the results of which will be pivotal to its New Drug Application with the FDA.
AusMedtech registrations launched
22 March, 2012 by AusBiotechEarly bird registration is now available for the 2012 AusMedtech national conference to be held in Sydney, Australia’s medical technology hub.
Intellectual property reform passes House of Reps
21 March, 2012 by Tim DeanThe Raising the Bar Bill that reforms Australia’s intellectual property laws has passed both houses of parliament and will soon be signed into law.
HealthLinx ready for South Korean OvPlex trial
21 March, 2012 by Dylan Bushell-EmblingMelbourne's HealthLinx (ASX:HTX) has taken another step towards gaining regulatory approval to sell OvPlex in South Korea, by laying the groundwork for a trial.
